Inventor · disambiguated record
Walter A. Blattler
Also filed as: BLAETTLER WALTER · BLAETTLER WALTER A · BLATTLER WALTER · BLATTLER WALTER A
47 granted patents·20 pending applications·8,829 citations·filing 1984–2025
99Inventor score
Top patents by PatentIndex Score
67 records- 0199US9683048B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 20, 2017·115 cites·144 claims
- 0299US7276499B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2006·Granted Oct 2, 2007·58 cites·21 claims
- 0399US6630579B2Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Oct 7, 2003·547 cites·16 claims
- 0499US6436931B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Aug 20, 2002·184 cites·24 claims
- 0599US6340701B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Jan 22, 2002·271 cites·24 claims
- 0699US5846545ATargeted delivery of cyclopropylbenzindole-containing cytotoxic drugsIMMUNOGEN INC·Filed 1995·Granted Dec 8, 1998·531 cites·57 claims
- 0799US5585499ACyclopropylbenzindole-containing cytotoxic drugsIMMUNOGEN INC·Filed 1995·Granted Dec 17, 1996·541 cites·8 claims
- 0899US5475092ACell binding agent conjugates of analogues and derivatives of CC-1065IMMUNOGEN INC·Filed 1994·Granted Dec 12, 1995·668 cites·8 claims
- 0999US4569789AAcid-cleavable compound, use in protein conjugates and drug delivery systemsDANA FARBER CANCER INST INC·Filed 1985·Granted Feb 11, 1986·458 cites·17 claims
- 1099US4542225AAcid-cleavable compoundDANA FARBER CANCER INST INC·Filed 1984·Granted Sep 17, 1985·107 cites·20 claims
- 1198US10981990B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Apr 20, 2021·11 cites·30 claims
- 1298US10711060B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Jul 14, 2020·29 cites·5 claims
- 1398US9815898B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 14, 2017·35 cites·30 claims
- 1498US9605070B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2015·Granted Mar 28, 2017·67 cites·85 claims
- 1598US8163888B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesSTEEVES RITA M·Filed 2007·Granted Apr 24, 2012·101 cites·53 claims
- 1698US8088387B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesSTEEVES RITA M·Filed 2004·Granted Jan 3, 2012·146 cites·143 claims
- 1798US7989598B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesIMMUNOGEN INC·Filed 2007·Granted Aug 2, 2011·46 cites·53 claims
- 1898US7575748B1Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesGENENTECH INC·Filed 2006·Granted Aug 18, 2009·104 cites·27 claims
- 1998US7097840B2Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesIMMUNOGEN INC·Filed 2001·Granted Aug 29, 2006·266 cites·44 claims
- 2098US6706708B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Mar 16, 2004·71 cites·12 claims
- 2198US5416064ACytotoxic agents comprising maytansinoids and their therapeutic useIMMUNOGEN INC·Filed 1992·Granted May 16, 1995·1.3k cites·20 claims
- 2298US5208020ACytotoxic agents comprising maytansinoids and their therapeutic useIMMUNOGEN INC·Filed 1992·Granted May 4, 1993·2.4k cites·18 claims
- 2398US4625014ACell-delivery agentDANA FARBER CANCER INST INC·Filed 1984·Granted Nov 25, 1986·255 cites·28 claims
- 2498US4618492AAcid-cleavable compoundDANA FARBER CANCER INST INC·Filed 1985·Granted Oct 21, 1986·98 cites·6 claims
- 2597US8337856B2Methods of treatment using anti-ERBB antibody-maytansinoid conjugatesBLAETTLER WALTER·Filed 2007·Granted Dec 25, 2012·86 cites·8 claims
- 2697US8198417B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesSTEEVES RITA M·Filed 2007·Granted Jun 12, 2012·59 cites·65 claims
- 2796US10844135B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making saidIMMUNOGEN INC·Filed 2017·Granted Nov 24, 2020·7 cites·35 claims
- 2896US10752687B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Aug 25, 2020·6 cites·90 claims
- 2996US9908936B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Mar 6, 2018·23 cites·30 claims
- 3096US4764368AAcid-cleavable compoundDANA FARBER CANCER INST INC·Filed 1986·Granted Aug 16, 1988·57 cites·20 claims
- 3195US11155620B2Method of detecting TIM-3 using antibody molecules to TIM-3NOVARTIS AG·Filed 2019·Granted Oct 26, 2021·6 cites·20 claims
- 3295US7217819B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2005·Granted May 15, 2007·22 cites·6 claims
- 3394US11827704B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2020·Granted Nov 28, 2023·2 cites·43 claims
- 3494US7585857B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2007·Granted Sep 8, 2009·15 cites·25 claims
- 3593US10472419B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 12, 2019·12 cites·57 claims
- 3693US9884913B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Feb 6, 2018·12 cites·30 claims
- 3793US7008942B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2003·Granted Mar 7, 2006·24 cites·17 claims
- 3892US7528130B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2006·Granted May 5, 2009·5 cites·28 claims
- 3990US7476669B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2007·Granted Jan 13, 2009·8 cites·29 claims
- 4090US2025066479A1Antibody molecules to pd-1 and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 4189US7550609B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2007·Granted Jun 23, 2009·7 cites·28 claims
- 4287USRE43899ECompositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsIMMUNOGEN INC·Filed 2012·Granted Jan 1, 2013·4 cites·21 claims
- 4384USRE44704ECompositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsCHARI RAVI V J·Filed 2012·Granted Jan 14, 2014·3 cites·16 claims
- 4482US2025213684A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2024·Application pending·0 cites
- 4580US5239062ABlocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicityDANA FARBER CANCER INST INC·Filed 1990·Granted Aug 24, 1993·43 cites·99 claims
- 4678US4888415AGelonin immunotoxinDANA FARBER CANCER INST INC·Filed 1988·Granted Dec 19, 1989·49 cites·10 claims
- 4778US2022185883A1Method of detecting tim-3 using antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
- 4877US2021261683A1Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesIMMUNOGEN INC·Filed 2020·Application pending·0 cites
- 4975US2025382365A1Antibody molecules to lag-3 and uses thereofNOVARTIS AG·Filed 2025·Application pending·0 cites
- 5073US12252535B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Mar 18, 2025·0 cites·10 claims
Showing the top 50 of 67 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →